321-50-6

Basic information

• Product Name: 7-FLUORO-1-H-BENZO[D][1,3]OXAZINE-2,4-DIONE
• Synonyms: 7-FLUORO-2H-3,1-BENZOXAZINE-2,4(1H)-DIONE;7-Fluoro-1H-benzo[d][1,3]oxazine-2,4-dione;2H-3,1-Benzoxazine-2,4(1H)-dione, 7-fluoro-;7-Fluoroisatoic anhydride;7-Fluoro-2H-3,1-benzoxazine-2,4(1H)-dione, 7-Fluoro-1H-benzo[d][1,3]oxazine-2,4-dione;7-fluoro-1H-3,1-benzoxazine-2,4-dione
• CAS NO: 321-50-6
• Molecular Formula: C₈H₄FNO₃
• Molecular Weight: 181.12
• Mol File: 321-50-6.mol

Chemical Properties

• Melting Point: 229-231 °C (decomp)
• Appearance: /
• Density: 1.503 g/cm³
• Refractive Index: 1.561
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.91±0.20(Predicted)
• CAS DataBase Reference: 7-FLUORO-1-H-BENZO[D][1,3]OXAZINE-2,4-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-FLUORO-1-H-BENZO[D][1,3]OXAZINE-2,4-DIONE(321-50-6)
• EPA Substance Registry System: 7-FLUORO-1-H-BENZO[D][1,3]OXAZINE-2,4-DIONE(321-50-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 321-50-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
7-FLUORO-1-H-BENZO[D][1,3]OXAZINE-2,4-DIONE is used as a key intermediate in the synthesis of various drugs and biologically active compounds. Its unique structure and reactivity contribute to the development of novel therapeutic agents with potential applications in treating a wide range of diseases and medical conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 7-FLUORO-1-H-BENZO[D][1,3]OXAZINE-2,4-DIONE is employed as a valuable building block for the creation of complex organic molecules. Its benzoxazine ring and dione functional group provide opportunities for further chemical modifications and reactions, enabling the synthesis of a diverse array of organic compounds with various applications.
Used in Fine Chemical Production:
7-FLUORO-1-H-BENZO[D][1,3]OXAZINE-2,4-DIONE plays a crucial role in the production of fine chemicals, which are high-purity chemicals used in various industries, including pharmaceuticals, agriculture, and materials science. Its properties and reactivity make it an essential component in the synthesis of specialty chemicals with specific functions and applications.

InChI:InChI=1/C8H4FNO3/c9-4-1-2-5-6(3-4)10-8(12)13-7(5)11/h1-3H,(H,10,12)

Upstream product

• 324-03-8 6-fluoroisatin 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 119023-25-5 4-fluoroanthranilamide 
• 399-51-9 6-fluoro-1H-indole 
• 75-44-5 phosgene 
• 446-32-2 4-fluoroanthranilic acid 
• 503-38-8 trichloromethyl chloroformate 

Downstream Products

• 76561-13-2 1-(2-amino-4-fluorophenyl)-2-methylsulfinylethanone 

Relevant articles and documents

New spiro pyrrole[2, 1-b]quinazolone derivative, preparation method and application thereof

The invention relates to a new spiro pyrrole[2, 1-b]quinazolone derivative, a preparation method and application thereof. The new spiro pyrrole[2, 1-b]quinazolone derivative is synthesized by using asimple method. The yield is high, the production cost is

Synthesis and nematicidal activities of 1,2,3-benzotriazin-4-one containing 4,5-dihydrothiazole-2-thiol derivatives against Meloidogyne incognita

A series of novel 1,2,3-benzotriazin-4-one derivatives containing 4,5-dihydrothiazole-2-thiol were synthesized and characterized by 1H NMR, 13C NMR, 19F NMR and HRMS. The bioassay results showed that compounds 3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)-7-methoxybenzo[d][1–3]triazin-4(3H)-one, 3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)-6-nitrobenzo[d][1–3]triazin-4(3H)-one, 7-chloro-3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)benzo[d][1–3]triazin-4(3H)-one exhibited good control efficacy against the cucumber root-knot nematode disease caused by Meloidogyne incognita at the concentration of 10.0 mg L?1 in vivo. Compound 7-chloro-3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)benzo[d][1–3]triazin-4(3H)-one showed excellent nematicidal activity with inhibition 68.3% at a concentration of 1.0 mg L?1. It suggested that the structure of 1,2,3-benzotriazin-4-one containing 4,5-dihydro-thiazole-2-thiol could be optimized further.

Synthesis of Ring-Fused, N-Substituted 4-Quinolinones Using p Ka-Guided, Base-Promoted Annulations with Isatoic Anhydrides: Total Synthesis of Penicinotam

An anionic annulation strategy employing isatoic anhydrides and a wide assortment of enolizable partners was developed to afford over 80 novel ring-fused, N-substituted 4-quinolinones, an underrepresented privileged template. Multiple factors governing the efficiency of the transformation were determined, resulting in a reliable and tunable synthetic platform applicable for a broad range of substrates with variable deprotonation susceptibility, such as tetramic and tetronic acids, cyclic 1,3-diketones, and cycloalkanones. Application to the synthesis of bioactive, pyrrolizine-fused 4-quinolinone, penicinotam 3, resulted in the most brief and highest yielding total synthesis of the alkaloid in three steps and a 36% overall yield.

Catalytic Asymmetric Synthesis of Atropisomeric Quinolines through the Friedl?nder Reaction

A phosphoric acid catalyzed atroposelective Friedl?nder reaction was developed in which acetylacetone and a variety of 2′-substituted 2-Aminobenzophenones were successfully employed to give optically active biaryl quinolines in good yields and with high enantioselectivities.

Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria

Drug-resistant malarial strains have been continuously emerging recently, which posts a great challenge for the global health. Therefore, new antimalarial drugs with novel targeting mechanisms are urgently needed for fighting drug-resistant malaria. NADH-ubiquinone oxidoreductase of Plasmodium falciparum (PfNDH2) represents a viable target for antimalarial drug development. However, the absence of structural information on PfNDH2 limited rational drug design and further development. Herein, we report high resolution crystal structures of the PfNDH2 protein for the first time in Apo-, NADH-, and RYL-552 (a new inhibitor)-bound states. The PfNDH2 inhibitor exhibits excellent potency against both drug-resistant strains in vitro and parasite-infected mice in vivo via a potential allosteric mechanism. Furthermore, it was found that the inhibitor can be used in combination with dihydroartemisinin (DHA) synergistically. These findings not only are important for malarial PfNDH2 protein-based drug development but could also have broad implications for other NDH2-containing pathogenic microorganisms such as Mycobacterium tuberculosis.

Mechanistic insights into a catalyst-free method to construct quinazolinones through multiple oxidative cyclization

A novel one-pot benign oxidative cyclization of alcohols with 2-aminobenzamides was successfully developed without catalyst to afford the quinazolinones under O2. This one-pot protocol involved oxidations and cyclizations to construct the skeleton of quinazolinones through possibly three kinds of distinct reaction mechanisms.

MACROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS

The present invention relates to Macrocyclic Compounds. The present invention also relates to compositions comprising at least one Macrocyclic Compound, and methods of using the Macrocyclic Compounds for treating or preventing HIV infection in a subject.

Synthesis and Nematicidal Activities of 1,2,3-Benzotriazin-4-one Derivatives against Meloidogyne incognita

A series of novel 1,2,3-benzotriazin-4-one derivatives were synthesized by the reaction of 3-bromoalkyl-1,2,3-benzotriazin-4-ones with potassium salt of 2-cyanoimino-4-oxothiazolidine in the presence of potassium iodide. Nematicidal assays in vivo showed that some of them exhibited good control efficacy against the cucumber root-knot nematode disease caused by Meloidogyne incognita, up to 100% at the concentration of 10.0 mg L-1, which indicated that 1,2,3-benzotriazin-4-one derivatives might be potential for novel promising nematicides. The nematicidal activity was influenced by the combination of substituent type, substituted position, and linker length in the molecule. The inhibition rate data at the concentrations of 5.0 and 1.0 mg L-1 for the compounds with high inhibitory activities were also provided. When tested in vitro, none of them showed direct inhibition against M. incognita. The investigation of a significant difference between in vivo and in vitro data is in progress.

MACROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS

The present invention relates to Macrocyclic Compounds. The present invention also relates to compositions comprising at least one Macrocyclic Compound, and methods of using the Macrocyclic Compounds for treating or preventing HIV infection in a subject.

MACROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS

Macrocyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G, Q, W, X, Y, Z, R',R2,R3,R4,R5 and R6 are as defined herein are disclosed. Compositions compris